Colossal Biosciences Opens Flagship Lab, Deepens De‑Extinction Bet
Context and Chronology
Colossal Biosciences this week opened a new, purpose-built research complex that consolidates its genetic, reproductive and field biology teams under one roof. The facility spans 55,000 sq ft and houses roughly 260 scientists and technicians focused on gene editing, cloning and systems biology. Mr. Lamm framed the space as an engineering platform intended to accelerate both de‑extinction projects and commercial spinouts. Investors have already committed substantial capital; the firm reports raising more than $600M and carrying a headline valuation near $10B, figures that reconfigure venture math for conservation tech.
Technically, the lab is sequencing ancient tissue, validating trait edits in model species and moving toward large‑mammal embryo workflows. Teams validated target coat and fat genes by producing two genetically modified mice with a woolly phenotype, and earlier work produced canids exhibiting selectable ‘‘dire wolf’’ traits. Dr. Shapiro explained that the group is combining paleogenomics with comparative elephant data to isolate candidate variants, then using somatic cell reprogramming and embryo engineering in pursuit of a deliverable organism. Their timeline projects a possible first birth in roughly two years, with surrogate gestation pegged at about 22 months.
Colossal is simultaneously structuring commercial pathways to monetize platform outputs rather than relying solely on headline projects. The company has spun off software, microbial and data businesses and announced a large cryobank initiative backed by partners in the United Arab Emirates. Those moves shift the narrative from single‑species theatrics to a multi‑product, IP‑rich model that appeals to VCs seeking repeatable revenue. Yet the same diversification raises questions about capital allocation between pure conservation and platform commercialization.
Critics have pushed back on ethics, ecological realism and the allocation of finite conservation dollars, warning that resurrected phenotypes may lack adaptive behaviors or viable niches. Academic experts flagged welfare risks for engineered animals and cautioned that phenotype mimicry does not equal ecological functional parity. Political actors have begun to reference de‑extinction in policy debates about conservation law, foreshadowing regulatory scrutiny that could alter field release and animal welfare pathways. That political attention now threatens to compress timelines for oversight and could force startups to design for compliance earlier than planned.
For the venture ecosystem, Colossal’s progress signals both opportunity and hazard: opportunity because platform tools — gene‑editing pipelines, reproductive engineering, data platforms, cryobanking — can be productized and scaled; hazard because high‑profile biological claims invite reputational and regulatory backlash that can derail exits. Founders and limited partners will watch whether near‑term milestones convert to durable revenue or whether headline science functions primarily as a capital‑raising vector. Either outcome will influence fundraising conditions for the next cohort of conservation‑oriented biotech startups.
Read Our Expert Analysis
Create an account or login for free to unlock our expert analysis and key takeaways for this development.
By continuing, you agree to receive marketing communications and our weekly newsletter. You can opt-out at any time.
Recommended for you
Thrive Capital raises a $10 billion fund to scale AI, space, robotics and life‑science bets
Thrive Capital closed a new fund that tops $10 billion, roughly double its prior vehicle, and declined additional commitments totaling multiple billions. The raise concentrates resources for investments in AI applications and infrastructure, space, robotics and life sciences — a dynamic that both intensifies competition for top startups and raises governance, vendor‑access and regulatory questions around concentrated ownership of AI leaders.
Sequoia Joins Anthropic Funding Push, Forcing a Rethink of VC Conflict Rules
Sequoia Capital is reported to be among the investors in a multibillion-dollar Anthropic financing that would sharply increase the AI startup’s private valuation and signal a softening of long-standing VC norms against backing direct rivals. The size and composition of the syndicate — including sovereign wealth, hedge funds and conditional strategic commitments from cloud and chip providers — also underscores investor interest in commercial-scale safety, observability and governance tooling as model builders race to scale.
REPROCELL launches StemEdit platform using AI-designed OpenCRISPR-1 to accelerate clinical iPSC editing
REPROCELL has introduced StemEdit, a clinical-focused gene editing service and off-the-shelf gene‑edited iPSC products built around OpenCRISPR-1, an AI-designed genome editor licensed from Profluent. The offering packages GMP-aligned workflows, traceability, and licensing clarity intended to shorten the path from development to first-in-human studies for cell therapy developers.
Regulatory Chokehold Threatens Lab-Grown Meat Rollout in the US and Europe
Startups producing cultivated meat are stalling because slow, unpredictable food approvals prevent them from scaling to retail; many firms are closing or shifting focus to restaurants or overseas markets. Without streamlined regulatory pathways and investment in large-scale cell biomass production, the sector risks losing momentum despite consumer interest and earlier investor enthusiasm.
OpenAI closes in on $100B-plus funding; valuation may exceed $850B
OpenAI is finalizing an initial tranche of a landmark financing expected to exceed $100 billion, which would push its pro forma value above $850 billion while leaving a pre-money valuation near $730 billion. Industry sources say talks with strategic backers — including advanced discussions with SoftBank for an incremental commitment roughly in the $30 billion range — could anchor the round, though no binding agreements have been announced.
DeepMind’s AlphaGenome decodes how DNA changes alter biology
DeepMind has unveiled AlphaGenome, an AI that links DNA sequence changes to biological function and can prioritize genetic variants for lab testing and drug discovery. Early benchmarks and real-world use show rapid uptake and strong performance, but the model still struggles with long-range regulation and tissue-specific effects and requires further validation.
Inside Physical Intelligence: Betting patient capital on general-purpose robot brains
A San Francisco startup led by Lachy Groom and academic founders is training general-purpose robotic foundation models using inexpensive arms and diverse real-world data rather than chasing immediate commercial deployments. Its research-first, compute-heavy strategy sits against an industry pivot toward rapid commercialization and infrastructure concentration, creating both a potential long-term advantage if models generalize and a near-term risk that revenue-led competitors entrench customers and data flywheels.
Flapping Airplanes raises $180M to pursue radical data‑efficient AI
Flapping Airplanes launched with a $180M seed to build foundation models that drastically cut data needs by pursuing algorithmic shifts inspired by the brain rather than scaling alone. The lab argues that radically better sample efficiency—publicly targeting gains as large as 1000x —could unlock robotics and scientific domains that are currently data‑starved, and it plans to prioritize cheap, small‑scale experiments before committing heavy compute.